CerebrumDX® Cerebrum DX® are a series of clinically verified, highly sensitive and specific multi-gene tests that analyze genes associated with hereditary neurological and developmental disorders. LEARN MORE Neurology Cerebrum DX® are a series of clinically verified, highly sensitive and specific multi-gene tests that analyze genes associated with hereditary neurological and developmental disorders. Kinetic Disorders (Parkinsons etc) Autisms Ataxias (SCA, FXTAS, FA etc) Neurogenetic Disorders (Alzheimer's, denentia etc) Neuromuscular Disorders (Congenital myasthenia gravis, M Amyotrophic lateral sclerosis etc.) Neuropathies and congenital neurodegenerative disorders (Hutington's disease, Parkinson's disease etc.) Epilepsy and seizures Cardiomyopathies and skeletal muscle disease and other Cerebrum DX® Ataxia, Cerebrum DX®, Cerebrum DX® Exome, Cerebrum DX® Arrays. The Cerebrum DX® assay analyzes over 4,500 genes associated with various neurological diseases. It is a comprehensive examination for the diagnosis, prognosis and management of disorders such as movement disorders, dystonia, dementia and others. The Cerebrum DX® Ataxia assay was created to diagnose and manage inherited disorders. Specifically, the analysis, depending on the phenotype, includes: A. Friedreich Ataxia Analysis (FA) by PCR-fragment analysis B. Analysis of Autosomal Dominant Cerebellar Ataxias (ADCA) SCA1, SCA2, SCA3, SCA6 & SCA7 On a negative result, the Cerebrum DX® analysis is suggested. The Cerebrum DX® Arrays analysis is based on the Microarrays method, where chromosomal abnormalities are analyzed and we can identify and diagnose developmental disorders and intervene accurately in their management. The Cerebrum DX® Exome analysis analyzes over 20,000 genes and is recommended for the diagnosis and management of cases where no finding has been found in gene panels, as well as in cases where the diagnosis is particularly demanding as in the case of ALS - Lateral Amyotrophic Sclerosis. Why CerebrumDX® molecular tests are important for: Diagnosis: Confirms the clinical diagnosis in a reliable and fast way and reduces the need for more invasive procedures (eg muscle biopsy, lumbar puncture, EMG). It is a useful tool for applying precision medicine to hereditary neurological disorders, minimizing dilemmas regarding the management of differential diagnosis, especially in disorders where the symptoms are milder, such as Myotonic Dystrophy Type 2 or the diagnosis is more demanding as in Spinal Muscular Atrophy and Autosomal dominant Cerebellar Ataxia. Prognosis: By knowing exactly the gene mutations that are responsible for a patient's disorder, we are able to predict its course, taking into account all the factors that concern the specific patient. We can also identify relatives who carry the same mutation and are at increased risk of developing the same disorder and be properly managed as appropriate. The contribution of the genetic test to disorders such as Myopathies is very important, where it helps in the prognosis of the patient but also in the monitoring and management of the disease within the family, indicating the need for prenatal control in each case. Management: The proper management of the patient and his/her family is based on the reliability of the diagnosis and prognosis of the disease, so that the physician is oriented towards the most appropriate treatment and monitoring. The genetic test offers an immediate answer to the physician as to the most appropriate therapeutic approach per patient case. A typical example is Duchenne Muscular Dystrophy, where diagnosis and management are based on genetic testing of the patient to detect and repair the dystrophin gene mutation. CerebrumDX® as a disease management tool: It helps to individualize the treatment based on the specific genotype of the patient and to avoid unnecessary medications and interventions. Recommends monitoring of other organs that may not have been examined before. It assists in family planning and acts as an advisory agent in establishing the necessary prenatal control. It can offer patients the opportunity to participate in clinical trials and newly developed targeted therapies. Test Genes Result Time CerebrumDX® >4.500 genes 25 working days CerebrumDX® Exome >20.000 genes 25 working days Test Genes & Ataxia Types CerebrumDX® Ataxia FXN SCA1, SCA2, SCA3, SCA6 & SCA7 10 working days 10 working days Test Analysis of Large Genomic Rearrangements CerebrumDX® Arrays CytoScan 750K Suite 750,000 markers ( includes polymorphic markers) 15 working days DISORDERS GENES AMYOTROPHIC LATERAL SCLEROSIS 38 MUSCULAR DISTROPHY 76 PARAPLEGIA 160 ATAXIAS 680 AUTISM 355 EPILEPSIES 1308 MYOPATHIES 205 PARKINSONISM 100 PARKINSON 40 DEMENTIA 142 MIGRAINES 82 HEMIPLEGIC MIGRAINE 26 NEUROMUSCULAR DISEASE 258 SPASTIC PARAPLEGIA 111 LEYKOENCEPHALOPATHY 169 The test is performed on blood (2 vials of blood with EDTA). International Directives • Recommended by EFNS / ENS for the diagnosis and management of various types of disorders. Recommended by the American Association of Pediatrics for the diagnosis and management of various types of epilepsy • Recommended by EFNS for the diagnosis and management of Parkinson's disease, Huntington's disease and dystonia • Recommended by ACMG for the diagnosis and management of autism • Recommended by EFNS for the diagnosis and management of amyotrophic lateral sclerosis For more scientific and technical information you can contact us: scientific.support@genekor.com About Contact us © 2017 GENEKOR MEDICAL S.A. All rights reserved | Terms of Use | Secure Transactions | Sitemap Committed to biotechnological innovation Change cookies consent Revoke cookies consent